|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM310603943 |
| 003 |
DE-627 |
| 005 |
20231225140443.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108455
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1035.xml
|
| 035 |
|
|
|a (DE-627)NLM310603943
|
| 035 |
|
|
|a (NLM)32479987
|
| 035 |
|
|
|a (PII)S1521-6616(20)30098-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Matsumori, Akira
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 01.02.2021
|
| 500 |
|
|
|a Date Revised 01.02.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a BACKGROUND: In this study, we measured immunoglobulin free light chains (FLC), a biomarker of inflammation in the sera of patients with heart failure due to myocarditis
|
| 520 |
|
|
|a METHODS: FLC kappa and FLC lambda were assayed in stored serum samples from patients with heart failure with myocarditis from the US myocarditis treatment trial by a competitive-inhibition multiplex Luminex® assay
|
| 520 |
|
|
|a RESULTS: The median concentration of circulating FLC kappa/lambda ratio was significantly lower in the sera from patients with heart failure with myocarditis than in healthy controls, and FLC kappa/lambda ratio had good diagnostic ability for identification of heart failure with myocarditis. Further, FLC kappa/lambda ratio was an independent prognostic factor for overall survival, and allowed creation of three prognostic groups by combining with N-terminal pro-B-type natriuretic peptide
|
| 520 |
|
|
|a CONCLUSIONS: This study suggests that FLC kappa/lambda ratio is a promising biomarker of heart failure with myocarditis
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Heart failure
|
| 650 |
|
4 |
|a Immunoglobulin
|
| 650 |
|
4 |
|a Immunology
|
| 650 |
|
4 |
|a Inflammation
|
| 650 |
|
4 |
|a Myocarditis
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin kappa-Chains
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin lambda-Chains
|2 NLM
|
| 650 |
|
7 |
|a NF-kappa B
|2 NLM
|
| 700 |
1 |
|
|a Shimada, Toshio
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakatani, Eiji
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shimada, Miho
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tracy, Steven
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chapman, Nora M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Drayson, Mark T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hartz, Vernon L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mason, Jay W
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 217(2020) vom: 30. Aug., Seite 108455
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:217
|g year:2020
|g day:30
|g month:08
|g pages:108455
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108455
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 217
|j 2020
|b 30
|c 08
|h 108455
|